In June, we reported on KPMG, a “Big Four” accounting firm, putting out a Positive Report on Psychedelics. Today we have another major player, Morgan Stanley, releasing its view on the psychedelic medicine market.
Morgan Stanley’s Counterpoint Global team “shares their proprietary views on a big idea that has the potential to trigger far-reaching consequences, and they’ve put a brief 4-page report on the potential for psychedelics to disrupt health care.
“Early results indicate that psychedelic therapy has the potential to fundamentally reshape how we think about and treat not only mental illness but a host of other conditions as well.”
In terms of content, there’s nothing really new here for experienced readers in the space; it’s more of an introduction to the sector for mainstream investors. Which is in itself the big news. Psychedelic medicine’s acceptance by large institutions and institutional investors will be one of the major factors deciding the sector’s future, and Morgan Stanley putting their name behind its potential will definitely help speed things along.
“Beyond mental illness and pain-related diseases, psychedelics have the potential to treat any disease where new neural pathways might improve function.”
The authors point out the lack of innovation in the field of mental health treatment, highlighting a need with serious market potential. They also discuss the relatively poor efficacy of current medications and that psychedelics’ path towards regulatory approval is already underway.
Overall, a pretty positive introduction to psychedelics, and a small yet significant step forward for the industry.
See here for the full report.
